💊 AbbVie off to a good start in 2025: Immunology pulls growth, obesity drug as a new opportunity! Pharma giant AbbVie $ABBV has started this year in very solid shape. The first quarter results exceeded market expectations and point to a successful transformation of the company's portfolio after a decline in revenue from Humira (an autoimmune disease treatment).
💊 AbbVie beats expectations: shares rise thanks to strong results and optimistic outlook! 🚀
Shares of biotech giant AbbVie $ABBV are up more than 4 %, after announcing better-than-expected quarterly earnings while raising its long-term outlook. Sales of Skyrizi and Rinvoq were a key driver of growth , offsetting declines in the once-flagship drug Humira.
For me, this is a very high quality company that last year and this year will reduce earnings per share. However, growth should return in the coming years. The dividend is also attractive. The potential for the future is certainly there.
Healthcare sector, one of the most popular sectors for investors, especially value investors. What are we going to think, health is the one thing we should protect most in our lives, and companies that are involved in this will profit from it perhaps indefinitely. Thanks to them, our society is able to live to a ripe old age. who are your favourites in this sector? For me, I... Read more
pharmaceutical company $ABBV is still going down at the moment. I have a buy threshold of 100, is anyone also thinking of buying when it goes down further or maybe even at this price?
Charlie Munger and his view of healthcare in the US.
Charlie, a friend, partner of Warren, has recently been vocal about his concerns about US healthcare, literally stating that it is a system that prolongs death to make more money and comparing patients to African carcasses. 🤔
The results were good, but I find $PFE and $LLY more interesting.